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Abstract
Background: Exhaled nitric oxide (NO) measurement has been shown to be a valuable tool in
the management of patients with asthma. Up to now, most measurements have been done with
stationary, chemiluminescence-based NO analysers, which are not suitable for the primary health
care setting. A hand-held NO analyser which simplifies the measurement would be of value both
in specialized and primary health care. In this study, the performance of a new electrochemical
hand-held device for exhaled NO measurements (NIOX MINO) was compared with a standard
stationary chemiluminescence unit (NIOX).
Methods: A total of 71 subjects (6–60 years; 36 males), both healthy controls and atopic patients
with and without asthma were included. The mean of three approved exhalations (50 ml/s) in each
device, and the first approved measurement in the hand-held device, were compared with regard
to NO readings (Bland-Altman plots), measurement feasibility (success rate with 6 attempts) and
repeatability (intrasubject SD).
Results: Success rate was high (≥ 84%) in both devices for both adults and children. The subjects
represented a FENO range of 8–147 parts per billion (ppb). When comparing the mean of three
measurements (n = 61), the median of the intrasubject difference in exhaled NO for the two
devices was -1.2 ppb; thus generally the hand-held device gave slightly higher readings. The Bland-
Altman plot shows that the 95% limits of agreement were -9.8 and 8.0 ppb. The intrasubject median
difference between the NIOX and the first approved measurement in the NIOX MINO was -2.0
ppb, and limits of agreement were -13.2 and 10.2 ppb. The median repeatability for NIOX and
NIOX MINO were 1.1 and 1.2 ppb, respectively.
Conclusion: The hand-held device (NIOX MINO) and the stationary system (NIOX) are in
clinically acceptable agreement both when the mean of three measurements and the first approved
measurement (NIOX MINO) is used. The hand-held device shows good repeatability, and it can be
used successfully on adults and most children. The new hand-held device will enable the
introduction of exhaled NO measurements into the primary health care.
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Background
Since the original reports of the presence of nitric oxide
(NO) in exhaled breath of mammals including humans
[1], and of the increased levels in subjects with asthma [2],
there has been a rapidly increasing interest in the meas-
urement of exhaled NO. The concentration of NO in
exhaled breath relates to the degree of eosinophilic
inflammation in the airways [3-5], and NO measurement
has been shown to be a valuable tool both to diagnose
[6,7] and to monitor the therapy of patients with asthma
[8,9].
Up to now, a single type of NO analyser has been used for
nearly all measurement of exhaled NO: the chemilumi-
nescence NO analyser [10]. These instruments are based
on a technology developed in the 1970's [11] and were
originally used for environmental and atmospheric analy-
ses. The chemiluminescence-based NO analysers are fast-
responding, highly sensitive (detection limit 1 parts per
billion (ppb) or lower) and specific for NO gas. However,
they are also rather bulky and expensive, and they need to
be calibrated on site, drawbacks that have been limiting
factors for the introduction of exhaled NO measurements
in routine clinical work. An alternative would be to use
electrochemical sensors, but they have not been sensitive
enough for analysis of NO in the low ppb range. Recently,
however, a new electrochemical sensor has been devel-
oped, based on the amperometric technique (the produc-
tion of a current when a potential is applied between two
electrodes), which is suitable for NO analysis in exhaled
breath [12]. This sensor has been incorporated into a
hand-held measuring device that complies with interna-
tional guidelines for exhaled NO measurements [13].
In this study, the new hand-held device was compared to
a chemiluminescence-based stationary device for exhaled
NO measurements that has previously proven to provide
repeatable results [14]. Both these instruments are now
cleared for clinical use in Europe and the stationary device
has also been cleared by the US Food and Drug Adminis-
tration [15]. The two devices were compared with regard
to NO readings, measurement repeatability and feasibil-
ity, in a sample of 71 children and adults with and with-
out asthma.
Methods
Subjects
Subjects were consecutively recruited at two separate clin-
ics (adult and pediatric) at Uppsala University Hospital. A
total of 75 subjects were invited; 34 adults (6 males, 38 ±
11 years; mean ± SD) and 41 children (30 males, 12 ± 3
years). The total age range was 6–60 years. Twentyone
subjects were non-atopic healthy controls, 52 subjects
were atopic and 39 subjects had a diagnosis of asthma.
None of the subjects had used any of the NO instruments
over the preceding 6 months and were thus considered
unexperienced with NO measurements. Subjects with a
FENO (fraction of expired NO) value of < 8 ppb were
excluded (tested with the chemiluminescence-based
instrument). At the time of the study, the detection limit
for the hand-held device was considered to be 8 ppb. This
has later been corrected by the manufacturer (see Table 1).
The study was approved by the regional ethics committee
and all subjects gave written informed consent.
Experimental protocol
Under guidance of clinical personnel, all subjects inhaled
NO-free air (built-in NO scrubbers) to close to total lung
capacity and exhaled during 10 s at a flow rate of 50 ml/s
to provide three approved FENO measurements in each of
the two devices (NIOX® Nitric Oxide Monitoring System
(NIOX) and NIOX MINO® Airway Inflammation Monitor
(NIOX MINO); Aerocrine AB, Solna, Sweden). Oral pres-
sure was measured and the subjects were instructed to
keep the pressure between 12–18 cmH2O in both devices
with the help of visual feedback (provided via a mirror in
NIOX MINO). Exhalation flow rate was kept at 50 ± 5 ml/
s with calibrated dynamic flow resistors in both devices. In
the NIOX, the mean NO concentration over the last 3 s of
exhalation is calculated and the NO plateau is evaluated
by linear regression, whereas in the NIOX MINO, the last
3-s portion of exhaled air is led into the measurement
chamber containing the sensor. Analysis takes 100 s
before a result representing the NO concentration in this
mixed gas portion is presented. Sampling technique in
both devices complies with current international guide-
lines [13]. The instruments are further described in Fig 1
and Table 1.
Measurements were performed in randomized device
order (at most 6 attempts per device). The mean of three
measurements in each device, or the first approved meas-
urement in the NIOX MINO were used for agreement
studies. After these measurements, subjects also
attempted one valid FENO  measurement (at most 3
attempts) in the hand-held device in a simulated home-
use environment where each subject performed the FENO
measurement without the assistance of clinical personnel.
Statistics
Data are presented as arithmetic mean ± standard devia-
tion (SD), or median [interquartile range] when appropri-
ate. For comparison between devices, intraclass
correlation coefficients (ICCs) were calculated and pre-
sented as reliability coefficients, and Bland-Altman plots
were constructed. Repeatability was calculated from
intrasubject SD. Student's paired t-test was used to com-
pare the mean number of attempts in the two devices. The
success rate was calculated as the proportion of subjects
succeeding in obtaining three valid FENO measurementsRespiratory Research 2006, 7:67 http://respiratory-research.com/content/7/1/67
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out of a maximum of six attempts in each device, or one
successful measurement out of a maximum of three
attempts using the NIOX MINO in the simulated home
use. Differences in success rate was evaluated by Fisher's
exact test.
Results
Success rate for approved measurements
Four subjects out of 75 had FENO measurements < 8 ppb
and were excluded from the study. They were all younger
children (age ≤ 13 years). Of all subjects (n = 71) who
made an attempt to use the NIOX or the NIOX MINO
under guidance of clinical personnel, only a few failed to
obtain three approved FENO measurements out of a maxi-
mum of 6 attempts (Table 2). These were primarily
younger children (age ≤ 13 years) who failed when
attempting to use the NIOX MINO (6 out of 7). The study
subjects were similarly successful in a simulated home-use
environment using the NIOX MINO where subjects were
to obtain one approved measurement out of three
attempts without guidance. There was no significant dif-
ference in success rate between the NIOX and the NIOX
MINO, or between the clinical setting and the simulated
home use, except for children being slightly less successful
than adults when attempting to use the NIOX MINO (p <
0.05, Fisher's exact test).
In subjects that were successful in all three sets of meas-
urements (n = 61), the mean number of attempts required
to obtain three approved measurements was 3.8 ± 1.0 and
3.4 ± 0.8 for the NIOX and the NIOX MINO, respectively.
The number of attempts was significantly lower for the
NIOX MINO (p < 0.05; paired t-test). The mean number
of attempts required by successful patients to obtain one
approved measurement in the home-use environment
was 1.1 ± 0.3.
Appearance of devices Figure 1
Appearance of devices. Illustrations of (A) the NIOX and (B) the NIOX MINO. Note that the relative size is not propor-
tional (see Table 1 for device dimensions).
Mouth piece
Display
Measurement unit
Display
Mouth piece
Measurement unit
AB
Table 1: Device comparison. Some characteristics that are not 
identical in the two devices are given. Most other characteristics 
are similar, for example NO scrubbing of inhaled air and the 
exhalation flow control.
NIOX NIOX MINO
Measurement range (ppb) 1.5–200 5–300
Accuracy < 50 ppb: ± 2.5 ppb
≥ 50 ppb: ± 5%
< 50 ppb: ± 5 ppb
≥ 50 ppb: ± 10%
Visual feedback Computer screen Display via mirror
Calibration on site Yes No
Dimensions (cm) 50 × 30 × 40 24 × 13 × 10
Weight (kg) 40 0.8
Table 2: Success rate. Fraction of patients (%) that were able to 
achieve three accepted measurements out of at most 6 attempts 
under guidance (clinical setting), or one accepted measurement 
out of at most 3 attempts without guidance (simulated home 
use).
Mode Clinical setting Home use
Instrument NIOX NIOX MINO NIOX MINO
All subjects (n = 71) 94 92 92
Children (n = 37) 95 84 84
Adults (n = 34) 94 100 100Respiratory Research 2006, 7:67 http://respiratory-research.com/content/7/1/67
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Three adverse eventswere reported (mental stress, throat
dryness, uncomfortable inhalation); they were all consid-
ered mild and were deemed unlikely to be caused directly
by the study devices.
Agreement between devices
The subjects represented a FENO range of 8–147 ppb. The
overall mean values for the NIOX and the NIOX MINO
were 26.5 ± 24.2 ppb and 27.5 ± 23.2 ppb (n = 63 and 62,
respectively). The reliability coefficient was high (r = 0.97)
when comparing the individual mean values in the two
devices (Fig 2A). The Bland-Altman plot shows agreement
between the NIOX and the NIOX MINO when comparing
the mean of three valid exhaled NO measurements (Fig
3A). The median of the intra-subject FENO difference was -
1.2 [-3.3, 0.8] ppb, suggesting that the NIOX MINO gave
FENO readings that were generally slightly higher than the
FENO measurements obtained using the NIOX. The 95%
limits of agreement were -9.8 and 8.0 ppb, which indi-
cates that for 95% of all subjects the difference between
FENO readings in NIOX and NIOX MINO is expected to lie
in the interval [-9.8, 8.0] ppb. The Bland-Altman plot
shows that the intrasubject FENO difference increased with
increasing FENO level (Fig 3A).
In addition, we find the same degree of agreement
between the NIOX and the NIOX MINO when comparing
the mean of three approved exhaled NO measurements in
the NIOX and the first approved measurement in the
NIOX MINO in the clinical setting (Fig 2B, 3B). The
median of the intra-subject FENO difference was -2.0 [-4.0,
1.0) ppb, again suggesting that FENO measurements with
NIOX MINO were slightly higher than FENO measure-
ments using NIOX. The 95% limits of agreement were -
13.2 and 10.2 ppb.
Measurement repeatability
Repeatability was similar in the NIOX and the NIOX
MINO. The 95th percentile for the distribution of the
repeatability (an estimate of the upper boundary of the
repeatabilityfor 95% of all subjects) in the NIOX was 3.3
ppb compared to 4.6 ppb in the NIOX MINO. The median
repeatability for NIOX and NIOX MINO was 1.1 [0.6, 1.6]
and 1.2 [0.6, 2.0] ppb, respectively. The real and estimated
distribution of intrasubject SDs are shown in Fig 4. One
extreme observation concerning the repeatability in the
NIOX MINO was noted (seen in Fig 4B). However, this
observation was not treated as an outlier in the popula-
tion.
Discussion
Exhaled NO has been studied extensively over the past
decade and reports of the clinical utility of this method in
the management of patients with asthma are now appear-
Device agreement Figure 2
Device agreement. Scatter plots of the mean of three valid FENO measurements using the NIOX vs (A) the mean of three 
valid FENO measurements, or vs (B) the first valid FENO measurement using the NIOX MINO (n = 61). Repeatability coefficients 
(ICCs) were (A) 0.97 and (B) 0.98, respectively (p < 0.001 for both).
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ing in the literature [8,9]. However, the introduction of
the method into clinical routine has been restricted by the
cost and complexity of existing NO analysers. In this
study, the performance of a new hand-held device for
exhaled NO measurements has been compared with that
of a standard stationary unit.
When we compare the mean of three valid FENO measure-
ments using the established chemiluminescence-based
NIOX and the NIOX MINO, which incorporates an elec-
trochemical sensor, the results suggest clinically accepta-
ble agreement between the two instruments. Measured
FENO levels obtained using the NIOX MINO were on aver-
age slightly higher than those obtained with the NIOX,
and there was a tendency that the intrasubject FENO differ-
ence increased with increasing FENO. We believe that the
difference between the two instruments is acceptable,
considering the different measurement technologies and
calibration procedures used in the two devices, and the
results are in conformity with the declared accuracy for
both the NIOX and the NIOX MINO. From a clinical
point of view, accuracy will be more important in a FENO
range close to a cut-off between health and disease (20–35
ppb) than at higher FENO levels. The NIOX MINO showed
good agreement (within 95% limits of agreement) with
the NIOX up to approximately 60 ppb, which indicates
that the new hand-held device will be able to give clinical
guidance with similar accuracy as the conventional chemi-
luminescence-based unit.
In general, the NIOX MINO and the NIOX had similar
repeatability, except for one extreme observation with
poor reproducibility in the NIOX MINO. However, this
was seen in a subject with very high exhaled NO values
(range 125–147 ppb in the NIOX MINO), and such vari-
ability at these high NO levels is of minor clinical impor-
tance. The repeatability agreed with the devices' technical
specifications.
Success rates in achieving the required number of accept-
able measurements were at least 84% for both devices and
for both subject groups. Since all subjects were considered
unexperienced with NO measurements, this indicates that
both measurement techniques are generally well accepted
by the patients. However, younger children failed slightly
more frequently than adults when attempting to use the
NIOX MINO. Interestingly, the number of attempts
needed for successful subjects to achieve three acceptable
measurements was significantly lower in the NIOX MINO
compared to the NIOX. This could at least partly be
explained by the fact that some measurements in the
NIOX may be discarded after a linear regression analysis
of the NO plateau has been performed, even though the
number of regression failures was not recorded in the
Device agreement Figure 3
Device agreement. Bland-Altman plots of the mean of three valid FENO measurements using the NIOX vs (A) the mean of 
three valid FENO measurements, or vs (B) the first valid FENO measurements using the NIOX MINO (n = 61).
A BRespiratory Research 2006, 7:67 http://respiratory-research.com/content/7/1/67
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present study. The linearized plateau must not deviate
more than 10% from the horizontal axis according to cur-
rent guidelines [13]. In the NIOX MINO, the NO level in
the last 3-s portion of mixed exhaled air is analyzed. Thus,
the need for an analysis of the quality of a real-time NO
plateau is avoided in the hand-held instrument.
Four subjects were excluded because of a low exhaled NO
value (< 8 ppb). However, three of these subjects had a
measurement above 5 ppb which is now the established
lower detection limit of the NIOX MINO.
During the simulated home use, subjects were given the
opportunity to use the NIOX MINO unassisted by study
staff (children were assisted by their parents as they likely
would be at home). This was performed after the clinical
session, which would imitate what would normally hap-
pen, namely that the patient would receive training in the
clinic prior to taking home the device. All subjects that
succeeded in the clinical setting also succeeded in the sim-
ulated home environment. Using the mean of three meas-
urements was advised in earlier guidelines [16], but this
was recently changed to two measurements [13]. We
found essentially the same agreement between the two
devices when comparing the mean of three valid measure-
ments in the NIOX and the first valid measurement in the
NIOX MINO. We thus suggest that one measurement is
adequate when using the NIOX MINO, which would save
valuable time in the clinic. The time for NO analysis in the
NIOX MINO is 100 s, but since one measurement seems
to be adequate in most instances, the total measurement
time will still be acceptable.
Conclusion
The results show that there is clinically acceptable agree-
ment between the stationary NIOX and the new hand-
held NIOX MINO, when similar conditions were consid-
ered and examinations were made as consistently as pos-
sible. The repeatability of measurements done using the
hand-held device was similar to the stationary device, and
adults and most children were able to successfully use
both instruments. In addition, subjects displayed ability
to operate the new hand-held device in a simulated home-
use environment. The new hand-held instrument will
enable the introduction of exhaled NO measurements in
the primary health care.
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Repeatability Figure 4
Repeatability. Histograms of the intra-subject SD of three valid FENO measurements using (A) the NIOX (n = 63) and (B) the 
NIOX MINO (n = 62). The estimated distribution of SD is indicated with the line.
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